Active Ingredient History
Methylene blue, also known as methylthioninium chloride, is a medication from WHO's list of essential medicines. Upon administration, methylene blue is converted to leukomethylene blue by erythrocyte methemoblobin reductase in the presence of NADPH. Leukomethylene blue than reduces methemoglobin to oxyhemoglobin, thus restoring oxygen carrying capacity of the blood. Methylene blue is also used as a dye for various diagnostic procedures, for treatment of ifosfamide toxicity and for in vitro staining. Historically, it was used as a photosensitizer for photodynamic therapy for topical treatment of dermatologic or mucocutaneous infections, as an antidote for cyanide poisoning, but these applications are no longer approved. Methylene blue is investigated in clinical trials for treatment of septic shock and Alzheimer's disease. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Abscess (Phase 2)
Acute Kidney Injury (Phase 2)
Adenocarcinoma of Lung (Phase 1)
Aging (Phase 2)
Airway Extubation (Phase 4)
Alzheimer Disease (Phase 2)
Bile Duct Neoplasms (Phase 3)
Bipolar Disorder (Phase 3)
Brain Diseases (Early Phase 1)
Breast Neoplasms (Phase 2)
Carcinoma, Adenoid Cystic (Phase 1)
Carcinoma, Basal Cell (Phase 1/Phase 2)
Carcinoma, Hepatocellular (Phase 1/Phase 2)
Carcinoma, Mucoepidermoid (Phase 1)
Carcinoma, Non-Small-Cell Lung (Phase 1)
Carcinoma, Squamous Cell (Phase 2)
Carcinoma, Verrucous (Phase 2)
Cheilitis (Phase 4)
Cholangiocarcinoma (Phase 3)
Cognition Disorders (Phase 2)
Cognitive Dysfunction (Phase 2)
Colonoscopy (Phase 2)
Colorectal Neoplasms (Phase 3)
Coronary Artery Disease (Phase 2)
COVID-19 (Phase 2)
Cross Infection (Phase 2)
Deficiency Diseases (Phase 1)
Dental Implantation (Phase 4)
Diabetes Mellitus (Early Phase 1)
Diabetic Foot (Early Phase 1)
Dysuria (Phase 3)
Gallbladder Neoplasms (Phase 3)
Gastrointestinal Neoplasms (Early Phase 1)
General Surgery (Phase 2)
Glucose-6-Phosphate (Phase 1)
Graft vs Host Disease (Phase 1)
Granuloma (Phase 1)
Head and Neck Neoplasms (Phase 2)
Healthy Volunteers (Phase 1)
Heart Valve Diseases (Phase 2)
Hemoglobins (Phase 1)
Hidradenitis Suppurativa (Phase 2)
Hypotension (Phase 2)
Inflammation (Phase 2)
Iron Deficiencies (Phase 4)
Jaundice (Phase 1)
Keratosis, Actinic (Phase 4)
Lasers (Phase 4)
Leukoplakia, Oral (Phase 1)
Liver Cirrhosis (Phase 4)
Liver Diseases (Phase 3)
Liver Neoplasms (Phase 2)
Liver Transplantation (Phase 4)
Lung Neoplasms (Phase 1)
Lymphedema (Phase 2)
Lymphoma, Non-Hodgkin (Phase 1)
Malaria (Phase 2)
Malaria, Falciparum (Phase 2)
Mesothelioma (Phase 2)
Methemoglobinemia (Phase 1)
Nasopharyngeal Neoplasms (Phase 1)
Neonatal Sepsis (Phase 2)
Neoplasm Metastasis (Phase 2)
Neoplasms (Early Phase 1)
Neovascularization, Pathologic (Phase 2/Phase 3)
Nervous System Malformations (Early Phase 1)
Neuroblastoma (Phase 1)
Oropharyngeal Neoplasms (Phase 1)
Pain (Phase 1)
Pancreatic Neoplasms (Phase 1)
Papilloma, Inverted (Phase 1)
Precancerous Conditions (Phase 2)
Prostatic Hyperplasia (Phase 1/Phase 2)
Prostatic Neoplasms (Phase 1)
Salivary Gland Neoplasms (Phase 1)
SARS-CoV-2 (Phase 1)
Sepsis (Phase 4)
Sezary Syndrome (Phase 1)
Shock (Phase 4)
Shock, Septic (Phase 3)
Skin Neoplasms (Phase 1)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stomatitis (Early Phase 1)
Stress Disorders, Post-Traumatic (Phase 2)
Surgical Wound Infection (Phase 2)
Thyroid Neoplasms (Phase 1)
Tongue Neoplasms (Phase 2)
Ureteral Diseases (Phase 2)
Urinary Tract Infections (Phase 4)
Uterine Cervical Neoplasms (Phase 1)
Vasoplegia (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
